Bionano Genomics announces publication of study on OGM

Bionano Genomics (BNGO) announced the publication of a study in Cancers from The University of Texas MD Anderson Cancer Center showing how optical genome mapping, OGM, can address key limitations of targeted RNA-sequencing panels in detecting therapeutically-relevant gene rearrangements in acute leukemias. This peer-reviewed publication, entitled “Comparative Analysis of Targeted RNA-Seq and Optical Genome Mapping for Detecting Gene Rearrangements in Acute Leukemia,” is the first to describe the comparison of OGM and RNA-seq in cancer. “This study is a great representation of how the utility of OGM is continuing to expand,” said Erik Holmlin, PhD, president and CEO of Bionano. “With this comparison against RNA-seq, we believe OGM is growing its footprint in digital pathology where it is imperative to use tools that reveal the complete architecture of the cancer genome and capture cryptic events that other technologies miss. The combination of OGM and RNA-seq can deliver the most comprehensive analysis of genome to potentially impact disease classification, risk stratification, and therapeutic selection.”